Q2 2020 Targovax ASA Earnings Call Transcript
Ladies and gentlemen, welcome to the quarterly presentation of Targovax. My name is Ãystein Soug, I'm the CEO. And today, with me, I have Erik Digman Wiklund, who is the CBO or the Chief Business Officer, in charge of Business Development. Also in the room today is Torbjørn Furuseth, he's the CFO, and he will be available to answer questions about the finances after the presentation.
Today, of course, we're going through the quarter. But we will have a deep dive into the collaborations that we have signed over the last quarter, and we'll also go through the latest data that we have produced in the company. But before we do so, let me just remind you shortly about who we are and what we do in Targovax. So we are in the field of immune activation. And ONCOS-102 is a leader in this field. It's one of the most developed oncolytic viruses with more than 200 patients treated. And we have data not only in mono, but also in combination with chemotherapy and in combination with checkpoint inhibitors. In addition to that, we also have an exciting early
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
